Primary tumor ablation with IRE in a PCa mouse model, followed by anti-CTLA4 and anti-PD1 immune checkpoint inhibitors, induced a significant increase in both tissue-resident and circulating memory cytotoxic T-cells with T-cell receptors targeting PCa-specific antigen, SPAS-1.178 Subsequently, this work indicated that a tumor vaccine effect was achieved by the tissue-resident and circulating memory cytotoxic CD8+ T-cells, limiting the reintroduction of new PCa. Here, SPATA19 is linked to neoplasm.